Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Dec;14(6):238-45.
doi: 10.3747/co.2007.158.

Role of vaccine therapy in cancer: biology and practice

J Schlom  1 , J L Gulley, P M Arlen
Affiliations

Role of vaccine therapy in cancer: biology and practice

J Schlom et al. Curr Oncol. 2007 Dec.

Abstract

Vaccines constitute a potential new therapeutic approach for a range of human cancers. Unlike other therapeutics, vaccines initiate a dynamic process in the host immune system that can be exploited with subsequent therapies. Indeed, recent preclinical and clinical studies with cancer vaccines have provided evidence that this unique therapeutic modality should lead to consideration of new paradigms in both clinical trial design and endpoints and in combination therapies. The present article reviews and sets out a rationale for these new paradigms, with a focus on prostate cancer.

Keywords: Immunotherapy; cancer vaccine; clinical protocols; combination therapy; prostate cancer; vaccine.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16. - PubMed
    1. Therasse P, Eisenhauer EA, Verweij J. recist revisited: a review of validation studies on tumour assessment. Eur J Cancer. 2006;42:1031–9. - PubMed
    1. Tuma RS. Sometimes size doesn’t matter: reevaluating recist and tumor response rate endpoints. J Natl Cancer Inst. 2006;98:1272–4. - PubMed
    1. Gore ME, Escudier B. Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma. Oncology (Williston Park) 2006;20(suppl 5):19–24. - PubMed
    1. Hoos A, Parmiani G, Hege K, et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother. 2007;30:1–15. - PubMed

LinkOut - more resources